There are currently several strategies in the clinical pipeline aiming at providing new treatment options by combinatory targeting of angiogenic signaling59,60, and a bispecific IgG1 antibody harboring specificity for both VEGF and angiopoietin-2 (faricimab) was recently approved by the FDA to treat diabetic macular edema and AMD15,61,62. Here, VEGFA is linked to diabetic macular edema.